Precision Oncology Company - Guardant Health Amea

The Guardant360® assay is a breakthrough liquid biopsy that provides fast, accurate and comprehensive genomic results from a simple blood draw in approximately seven days upon receipt in the US laboratory. Since its launch in 2014, the Guardant360® assay has been ordered by more than 7,000 oncologists over 150,000 times for patients with advanced cancer to help select treatment.

GuardantOMNI™, launched in 2017, is designed for biopharmaceutical customers to use as a comprehensive genomic profiling tool to help accelerate clinical development programs in immuno-oncology and targeted therapy."

3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543

Tel no. 
+65 63056523 / +65 63056520


Email address:  

Contact this advertiser